Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMD Download PDF Antoine Balavoine2023-04-03T00:00:46+02:00April 3rd, 2023|Press Releases|
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Download PDF Antoine Balavoine2023-03-31T11:13:27+02:00March 31st, 2023|News, Press Releases|
Reduction of share capital due to losses by reduction of nominal value: number of shares unchanged Download PDF Antoine Balavoine2023-03-17T08:49:29+01:00March 17th, 2023|Other Regulated Information, Press Releases|
Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents Download PDF Lino Talfer2023-03-01T14:11:04+01:00February 28th, 2023|Press Releases, Shareholder's General Meeting|
Second convening of the Extraordinary Shareholder Meeting on March 8, 2023 Download PDF Antoine Balavoine2023-02-16T20:37:35+01:00February 16th, 2023|Press Releases, Shareholder's General Meeting|
Pixium Vision announces its cash position at 31 December 2022 and provides an update on its activities Download PDF Antoine Balavoine2023-02-14T22:40:31+01:00February 14th, 2023|Press Releases|
Pixium Vision announces termination of convertible note financing agreement with US-based healthcare investor ESGO Download PDF Antoine Balavoine2023-02-14T16:54:54+01:00February 13th, 2023|Press Releases|
Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents Download PDF Antoine Balavoine2023-01-27T17:45:49+01:00January 27th, 2023|Press Releases|
Pixium Vision convenes an Extraordinary General Meeting of Shareholders on February 15, 2023 Download PDF Antoine Balavoine2023-02-01T13:44:16+01:00January 20th, 2023|Press Releases|
Peer-reviewed publications demonstrating the potential of the Next Generation PRIMA implant Download the PDF Antoine Balavoine2023-01-12T19:25:18+01:00January 12th, 2023|Press Releases|